Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer

Published:2015-10 Issue:1 Volume:90 Page:71-77
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Narita Yusuke,Matsushima Yukiko,Shiroiwa Takeru,Chiba Koji,Nakanishi Yoichi,Kurokawa Tatsuo,Urushihara Hisashi

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int. J. Cancer,2015

2. Cancer Mortality (1958–2013);The Center for Cancer Control and Information Services,2014

3. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;D’Addario;Ann. Oncol.,2010

4. Chemotherapy for advanced stage non–small cell lung cancer;Fathi;Semin. Thorac. Cardiovasc. Surg.,2008

5. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non–small-cell lung cancer;Scagliotti;J. Clin. Oncol.,2008

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness Analysis of the Oncomine™ Dx Target Test MultiCDx System Using Next-generation Sequencing and Single-gene Test in Advanced and Recurrent Nonsquamous Non-small-cell Lung Cancer;JMA Journal;2024

2. Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer;Respiratory Investigation;2023-01

3. Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China;Cancer Management and Research;2021-11

4. Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials;Expert Opinion on Investigational Drugs;2021-08-22

5. Cost‐effectiveness of precision diagnostic testing for precision medicine approaches against non‐small‐cell lung cancer: A systematic review;Molecular Oncology;2021-07-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3